|Day's range||0.7000 - 0.7000|
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.
Here is how Adma Biologics (ADMA) and Novartis (NVS) have performed compared to their sector so far this year.
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, prevention of skeletal related complications in cancer that has spread to the bone and unresectable giant cell tumor of the bone1,2 Sandoz continues to build its biosimilars portfolio to increase patient access to high-
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis have been highlighted in this Screen of The Week article.
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
Dividend stocks W.W. Grainger (GWW), Graphic Packaging (GPK), PulteGroup (PHM), Walmart (WMT) and Novartis (NVS) could be solid choices for your portfolio.
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
Most readers would already be aware that Novartis' (VTX:NOVN) stock increased significantly by 15% over the past three...
Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.
Novartis Board of Directors approves the recommendation of Sandoz Chairman-designate for the future Sandoz Board of Directors, to start preparatory work in June, followed by formal constitution in H2 2023 Experienced and diverse group of corporate leaders with a track record of growing businesses and driving value for the organization and society will help set strategic direction for Sandoz and support its future development Basel, May 15, 2023 — Sandoz takes the next steps to prepare for the pl
Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.
Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III ASCEMBL trial reaffirm Scemblix superiority over Bosulif* in patients with chronic myeloid leukemia (CML) in chronic phase, previously treated with two or more tyrosine kinase inhibitors Preliminary global results from large-scale Survey on Unmet Needs in CML disrupt notion that CML is solved and underscore import
Novartis CEO pushes back against government attempts to direct pharma R&D
Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.